Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure

BMC Cardiovascular Disorders

Volumn 11, Issue , 2011, Pages

  Chabot, Andreanne ^a   Jiang, Bao H ^a   Shi, Yanfen ^a   Tardif, Jean Claude ^a,b   Dupuis, Jocelyn ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Myofibroblasts; Pulmonary heart disease; Pulmonary hypertension; Spironolactone

Indexed keywords

SPIRONOLACTONE; ALDOSTERONE; ALDOSTERONE ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART INFARCTION; HEART LEFT VENTRICLE; HEART PERFORMANCE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOLOGY; LUNG FIBROSIS; LUNG STRUCTURE; LUNG WEIGHT; MALE; MYOFIBROBLAST; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; TREATMENT DURATION; TREATMENT OUTCOME; ULTRASOUND; ANIMAL; DRUG EFFECT; ECHOGRAPHY; HEART FAILURE; HEART MUSCLE; HEART VENTRICLE REMODELING; LUNG; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CELL PROLIFERATION; ECHOCARDIOGRAPHY; HEART FAILURE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOFIBROBLASTS; RATS; RATS, WISTAR; SPIRONOLACTONE; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 82455168270     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-11-72     Document Type: Article

References (27)

1. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001, 37:183-188. 10.1016/S0735-1097(00)01102-5, 11153735.
2. Jiang BH, Tardif JC, Sauvageau S, Ducharme A, Shi Y, Martin JG, Dupuis J. Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure. J Card Fail 2010, 16:679-688. 10.1016/j.cardfail.2010.03.003, 20670847.
3. Jasmin JF, Calderone A, Leung TK, Villeneuve L, Dupuis J. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res 2003, 58:621-631. 10.1016/S0008-6363(03)00290-6, 12798435.
4. Prefontaine A, Calderone A, Dupuis J. Role of endothelin receptors on basal and endothelin-1-stimulated lung myofibroblast proliferation. Can J Physiol Pharmacol 2008, 86:337-342. 10.1139/Y08-024, 18516096.
5. Kingsbury MP, Huang W, Donnelly JL, Jackson E, Needham E, Turner MA, Sheridan DJ. Structural remodelling of lungs in chronic heart failure. Basic Res Cardiol 2003, 98:295-303. 10.1007/s00395-003-0419-6, 12955402.
6. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004, 125:669-682. 10.1378/chest.125.2.669, 14769751.
7. Jiang BH, Tardif JC, Shi Y, Dupuis J. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. Eur Respir J 2011, 37:578-586. 10.1183/09031936.00053710, 20595149.
8. Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med 1998, 92:1321-1325. 10.1016/S0954-6111(98)90136-6, 10197224.
9. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999, 341:709-717. 10.1056/NEJM199909023411001, 10471456.
10. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, . Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321. 10.1056/NEJMoa030207, 12668699, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
11. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, . EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21. 10.1056/NEJMoa1009492, 21073363, EMPHASIS-HF Study Group.
12. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-e90. 10.1016/j.jacc.2008.11.013, 19358937.
13. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA 2009, 302:1658-1665. 10.1001/jama.2009.1493, 19843900.
14. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001, 38:1227-1232. 10.1161/hy1101.099484, 11711528.
15. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99:2694-2701.
16. Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, Cattadori G, Palermo P. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J 2005, 26:159-164.
17. Zhao L, Zhao M, Fang Q. Spironolactone ameliorates rat pulmonary fibrosis induced by Sbleomycin a5. Zhonghua Jie He He Hu Xi Za Zhi 1998, 21:300-302.
18. . Institute of Laboratory Animal Research CoLS, National Research Council Guide for the care and use of laboratory animals 1996, Washington D.C.: National Academy Press, Institute of Laboratory Animal Research CoLS, National Research Council.
19. Jiang BH, Nguyen QT, Tardif JC, Shi Y, Dupuis J. Single measurement of troponin T for early prediction of infarct size, congestive heart failure, and pulmonary hypertension in an animal model of myocardial infarction. Cardiovasc Pathol 2011, 20:e85-89. 10.1016/j.carpath.2010.04.005, 20537565.
20. Lefebvre F, Prefontaine A, Calderone A, Caron A, Jasmin JF, Villeneuve L, Dupuis J. Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clin Sci (Lond) 2006, 111:217-224.
21. Nguyen QT, Colombo F, Rouleau JL, Dupuis J, Calderone A. Lu135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. Br J Pharmacol 2000, 130:1525-1530. 10.1038/sj.bjp.0703466, 1572223, 10928953.
22. Lal A, Veinot JP, Leenen FH. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res 2004, 64:437-447. 10.1016/j.cardiores.2004.08.004, 15537497.
23. Takeda M, Tatsumi T, Matsunaga S, Hayashi H, Kimata M, Honsho S, Nishikawa S, Mano A, Shiraishi J, Yamada H, Takahashi T, Matoba S, Kobara M, Matsubara H. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 2007, 30:427-437. 10.1291/hypres.30.427, 17587755.
24. Mill JG, Milanez Mda C, de Resende MM, Gomes Mda G, Leite CM. Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol 2003, 30:739-744. 10.1046/j.1440-1681.2003.03906.x, 14516412.
25. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Henry JP, Jeng AY, Webb RL, Thuillez C. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008, 29:2171-2179. 10.1093/eurheartj/ehn277, 18586661.
26. O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003, 14:479-488. 10.1016/S1359-6101(03)00055-8, 14563350.
27. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res 2008, 102:319-327. 10.1161/CIRCRESAHA.107.160408, 18079410.